Somatropin

In plain language

Somatropin is lab-made human growth hormone, identical to the hormone the pituitary gland makes. It is used in children with growth failure from growth hormone deficiency or specific genetic syndromes, and in adults with confirmed deficiency.

Brands include Genotropin, Norditropin and Humatrope. The FDA bans its use for anti-aging, athletic performance or normal short stature, and misuse carries real risks including joint pain, swelling and diabetes.

For students

Somatropin is recombinant 191-residue human growth hormone (about 22,124 Da), produced in engineered bacteria. The original product, somatrem (Protropin, 1985), carried an extra N-terminal methionine; pure somatropin followed in 1987. Cadaver-derived pituitary GH had caused fatal Creutzfeldt-Jakob disease in recipients, which made a safe synthetic supply a public health priority.

Approved indications include pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature (at restricted doses), small-for-gestational-age without catch-up growth, chronic renal insufficiency and adult GH deficiency. Its mechanism is partly direct and partly via hepatic IGF-1 induction. The 1990 Rudman study reporting lean mass gains in older men launched decades of off-label anti-aging use that the FDA and endocrine societies have consistently opposed, citing carpal tunnel, edema, insulin resistance and potential cancer-promoting concerns without established benefit.

For researchers and instructors

Biochemistry. A four-helix bundle cytokine-receptor-fold protein engaging the GH receptor as an asymmetric 1:2 complex (one hormone, two receptor molecules), a textbook example of receptor homodimerization by a single ligand.

Pharmacology. Daily (or, for some analogues, weekly) subcutaneous injection; dose-dependent IGF-1 response used for titration; adverse effects include intracranial hypertension, slipped capital femoral epiphysis in children, fluid retention and carbohydrate intolerance.

Human evidence. Registration trials across each indication, plus adult deficiency trials (about 5% improvements in body composition and lipid profiles) and long-term surveillance cohorts (e.g., KIGS, GeNeSIS) of hundreds of thousands of patient-years.

Teaching point. Teaches recombinant protein history, indication boundaries (the FDA's explicit anti-aging ban), and the ethics of enhancement versus treatment in endocrinology.